Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments to reduce the risk of hearing loss in children undergoing chemotherapy. Their primary product, PEDMARK®, is the first and only FDA-approved therapy for reducing the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. PEDMARK has also received Orphan Drug Exclusivity in the U.S. and European Commission approval, allowing for market protection and further expansion.

Fennec has been steadily growing its revenues with PEDMARK® since its launch in the United States in 2022. They have also secured a significant licensing deal with Norgine to commercialize PEDMARQSI® in Europe, Australia, and New Zealand. The company is committed to expanding its reach and making PEDMARK® more accessible to patients and providers globally, with a focus on the outpatient oncology community and the adolescent and young adult (AYA) population.

Fennec Pharmaceuticals is a biotechnology company focused on improving the lives of children with cancer who experience hearing loss as a result of chemotherapy. They are fiercely devoted to fighting ototoxicity, particularly in pediatric cancer patients who receive cisplatin-based chemotherapy, as young children are especially vulnerable due to their developing ears. Their mission is to protect children's hearing and prevent the permanent, severe, and profound impact of cisplatin-induced ototoxicity, which can significantly impair cognitive performance, social and language skills, and overall development.

Fennec Pharmaceuticals promotes a culture deeply rooted in its mission of improving the lives of children with cancer who experience hearing loss due to chemotherapy. The company's website emphasizes its dedication to this cause, highlighting the passion and commitment of its team. This translates to a work environment that values collaboration, innovation, and a shared sense of purpose in addressing a significant unmet medical need.

Fennec Pharmaceuticals, dedicated to improving the lives of children with cancer, has a strong commitment to diversity, equity, and inclusion (DE&I). This commitment is reflected in their Board of Directors, which includes individuals with diverse backgrounds and expertise, as well as in their efforts to ensure accessibility and representation in their scientific research and outreach to families. While the website does not explicitly state their specific DE&I initiatives, the company's focus on pediatric cancer care underscores their recognition of the importance of serving a diverse patient population.